

DAFTAR PUSTAKA

- Adigun, R. and Singh, R. (2022) *Tuberculosis*. Treasure Island. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK441916/?report=printable>.
- Alcaïs, A. *et al.* (2005) “Tuberculosis in children and adults: Two distinct genetic diseases,” *Journal of Experimental Medicine*, pp. 1617–1621. Available at: <https://doi.org/10.1084/jem.20052302>.
- Alemu, A. *et al.* (2021) “Predictors of mortality in patients with drug-resistant tuberculosis: A systematic review and meta-analysis,” *PLoS ONE*, 16(6 June). Available at: <https://doi.org/10.1371/journal.pone.0253848>.
- Alene, K.A. *et al.* (2017) “Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China,” *BMC Infectious Diseases*, 17(1). Available at: <https://doi.org/10.1186/s12879-017-2662-8>.
- Alene, K. A., Wangdi, K., & Clements, A. C. (2020). Impact of the COVID-19 pandemic on tuberculosis control: an overview. *Tropical medicine and infectious disease*, 5(3), 123.
- Al-Hajje, A. *et al.* (2015) “Factors affecting medication adherence in Lebanese patients with chronic diseases,” *Pharmacy Practice*, 13(3), p. 590. Available at: <https://doi.org/10.18549/PharmPract.2015.03.590>.
- Andreu, J. *et al.* (2004) “Radiological manifestations of pulmonary tuberculosis,” *European Journal of Radiology*, 51(2), pp. 139–149. Available at: <https://doi.org/10.1016/j.ejrad.2004.03.009>.
- Aragona, M. *et al.* (2020) “Negative impacts of COVID-19 lockdown on mental health service access and follow-up adherence for immigrants and individuals in socio-economic difficulties,” *Public Health*, 186, pp. 52–56. Available at: <https://doi.org/10.1016/j.puhe.2020.06.055>.
- Appulembang, I., Wujon, A. L. L., Briggs, D., & Abdullah, M. N. (2021). Factors Affecting Treatment Compliance In Tb Patients (Tuberculosis) During Pandemic Covid-19 At Labuang Baji Makassar Hospital. *International Journal of Health and Pharmaceutical (IJHP)*, 1(1), 11–16.
- Baek, S.H., Li, A.H. and Sasseti, C.M. (2011) “Metabolic regulation of mycobacterial growth and antibiotic sensitivity,” *PLoS Biology*, 9(5). Available at: <https://doi.org/10.1371/journal.pbio.1001065>.



- Behr, M.A. and Waters, W.R. (2014) “Is tuberculosis a lymphatic disease with a pulmonary portal?,” *The Lancet Infectious Diseases*, pp. 250–255. Available at: [https://doi.org/10.1016/S1473-3099\(13\)70253-6](https://doi.org/10.1016/S1473-3099(13)70253-6).
- Belton, M. *et al.* (2016) “Hypoxia and tissue destruction in pulmonary TB,” *Thorax*, 71(12), pp. 1145–1153. Available at: <https://doi.org/10.1136/thoraxjnl-2015-207402>.
- Birkmeyer, J.D. *et al.* (2020) “The Impact Of The COVID-19 Pandemic On Hospital Admissions In The United States,” *Health Affairs*, 39(11), pp. 2010–2017. Available at: <https://doi.org/10.1377/hlthaff.2020.00980>.
- Bollela, V.R. *et al.* (2016) “Detection of katG and inhA mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis,” *International Journal of Tuberculosis and Lung Disease*, 20(8), pp. 1099–1104. Available at: <https://doi.org/10.5588/ijtld.15.0864>.
- Boudville, D.A., Joshi, R. and Rijkers, G.T. (2020) “Migration and tuberculosis in Europe,” *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, 18. Available at: <https://doi.org/10.1016/j.jctube.2020.100143>.
- Byun, H. *et al.* (2022) “The impact of the COVID-19 pandemic on outpatients of internal medicine and pediatrics,” *Medicine*, 101(8), p. e28884. Available at: <https://doi.org/10.1097/MD.00000000000028884>.
- Chen, N. *et al.* (2020) “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study,” *The Lancet*, 395(10223), pp. 507–513. Available at: [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7).
- Chesov, D. *et al.* (2017) “High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova,” *European Respiratory Journal*. European Respiratory Society. Available at: <https://doi.org/10.1183/13993003.01340-2017>.
- Chiaradia, L. *et al.* (2017) “Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane,” *Scientific Reports*, 7(1). Available at: <https://doi.org/10.1038/s41598-017-12718-4>.
- Choi, S.E. *et al.* (2021) “Modeling the Impact of COVID-19 on Dental Insurance Coverage and Utilization,” *Journal of Dental Research*, 100(1), pp. 50–57. Available at: <https://doi.org/10.1177/0022034520954126>.
- Cruz, A.T. and Starke, J.R. (2007) “Clinical manifestations of tuberculosis in children,” *Paediatric*

- Cui, Y. *et al.* (2020) “A long-term trend study of tuberculosis incidence in china, india and united states 1992–2017: A joinpoint and age–period–cohort analysis,” *International Journal of Environmental Research and Public Health*, 17(9). Available at: <https://doi.org/10.3390/ijerph17093334>.
- Curvo-Semedo, L., Teixeira, L. and Caseiro-Alves, F. (2005) “Tuberculosis of the chest,” *European Journal of Radiology*, 55(2), pp.158–172. Available at: <https://doi.org/10.1016/j.ejrad.2005.04.014>.
- Damtei, D., Weldeyohannes, D. and Mathewos, B. (2014) “Review on Molecular Mechanism of First Line Antibiotic Resistance in Mycobacterium tuberculosis,” *Mycobacterial Diseases*, 04(06). Available at: <https://doi.org/10.4172/2161-1068.1000174>.
- Daniel, J. *et al.* (2004) “Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture,” *Journal of Bacteriology*, 186(15), pp. 5017–5030. Available at: <https://doi.org/10.1128/JB.186.15.5017-5030.2004>.
- Danilchanka, O. *et al.* (2015) “The mycobacterium tuberculosis outer membrane channel protein CpnT confers susceptibility to toxic molecules,” *Antimicrobial Agents and Chemotherapy*, 59(4), pp. 2328–2336. Available at: <https://doi.org/10.1128/AAC.04222-14>.
- Gashu, K.D., Gelaye, K.A. and Tilahun, B. (2021) “Adherence to TB treatment remains low during continuation phase among adult patients in Northwest Ethiopia,” *BMC Infectious Diseases*, 21(1). Available at: <https://doi.org/10.1186/s12879-021-06428-6>.
- Gast, A. and Mathes, T. (2019) “Medication adherence influencing factors—an (updated) overview of systematic reviews,” *Systematic Reviews*, 8(1), p. 112. Available at: <https://doi.org/10.1186/s13643-019-1014-8>.
- Gulliford, M. *et al.* (2002) “What does ‘access to health care’ mean?,” *Journal of Health Services Research & Policy*, 7(3), pp. 186–188. Available at: <https://doi.org/10.1258/135581902760082517>.
- Hett, E.C. and Rubin, E.J. (2008) “Bacterial Growth and Cell Division: a Mycobacterial Perspective,” *Microbiology and Molecular Biology Reviews*, 72(1), pp. 126–156. Available at: <https://doi.org/10.1128/mmbr.00028-07>.

- Huang, C. *et al.* (2020) “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” *The Lancet*, 395(10223), pp. 497–506. Available at: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- Indah Aderita, N., Murti, B. and Suryani, N. (2016) “Risk Factors Affecting Multi-Drug Resistant Tuberculosis in Surakarta and Ngawi, Indonesia,” *Journal of Epidemiology and Public Health*, 1(2), pp. 86–99. Available at: <https://doi.org/jepublichealth.2016.01.02.02>.
- Indonesia National TB Program Current status of integrated community based TB service delivery and the Global Fund work plan to find missing TB cases* (no date).
- Jaya, A. M., Harries, A. D., Rahman, A., Khogali, M., Chinnakali, P., & Gopal, B. (2022). Compliance with Medication amongst Persons with Diabetes Mellitus during the COVID-19 Pandemic, Kerala, India: A Cross Sectional Study. *Tropical Medicine and Infectious Disease*, 7(6). <https://doi.org/10.3390/tropicalmed7060104>
- Javed, B. *et al.* (2020) “The coronavirus (<scp>COVID</scp> -19) pandemic’s impact on mental health,” *The International Journal of Health Planning and Management*, 35(5), pp. 993–996. Available at: <https://doi.org/10.1002/hpm.3008>.
- Kandler, J.L. *et al.* (2018) “Validation of novel mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests,” *Antimicrobial Agents and Chemotherapy*, 62(10). Available at: <https://doi.org/10.1128/AAC.00974-18>.
- Kementerian Kesehatan Republik Indonesia (no date) *TB MDR - TBC Indonesia*. Available at: <https://tbindonesia.or.id/pustaka-tbc/informasi/teknis/tb-mdr/> (Accessed: March 7, 2022).
- Kichloo A, Albosta M, Dettloff K, & et al. (2020). Telemedicine, the current COVID-19 pandemic and the future: a narrative review and perspectives moving forward in the USA. *Fam Med Community Health*, 8(3), 53–60.
- Kliiman, K. and Altraja, A. (2009) “Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB,” *European Respiratory Journal*, 33(5), pp. 1085–1094. Available at: <https://doi.org/10.1183/09031936.00155708>.
- Knechel, N.A. (2009) “Tuberculosis: Pathophysiology, clinical features, and diagnosis,” *Critical Care Nurse*, 29(2), pp. 34–43. Available at: <https://doi.org/10.4037/ccn2009968>.
- Kumwihar, P., Chongsuvivatwong, V., & Prappre, T. (2022). Tuberculosis Treatment Compliance Under Smartphone-Based Video-Observed Therapy Versus Community-Based Directly Observed Therapy: Protocol for a Cluster Randomized Controlled Trial. *JMIR*

- Li, Q. *et al.* (2020) “Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus– Infected Pneumonia,” *New England Journal of Medicine*, 382(13), pp. 1199–1207. Available at: <https://doi.org/10.1056/NEJMoa2001316>.
- Luies, L. and Preez, I. du (2020) “The echo of pulmonary tuberculosis: Mechanisms of clinical symptoms and other disease-induced systemic complications,” *Clinical Microbiology Reviews*. American Society for Microbiology, pp. 1–19. Available at: <https://doi.org/10.1128/CMR.00036-20>.
- Maitra, A. *et al.* (2019) “Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles’ heel for the TB-causing pathogen,” *FEMS Microbiology Reviews*. Oxford University Press, pp. 548– 575. Available at: <https://doi.org/10.1093/femsre/fuz016>.
- Mathiasen, V.D. *et al.* (2020) “Clinical features of tuberculous lymphadenitis in a low-incidence country,” *International Journal of Infectious Diseases*, 98, pp. 366–371. Available at: <https://doi.org/10.1016/j.ijid.2020.07.011>.
- Maraba, N., Hoffmann, C. J., Chihota, V. N., Chang, L. W., Ismail, N., Candy, S., Madibogo, E., Katzwinkel, M., Churchyard, G. J., & McCarthy, K. (2018). Using mHealth to improve tuberculosis case identification and treatment initiation in South Africa: Results from a pilot study. *PloS One*, 13(7), e0199687. <https://doi.org/10.1371/journal.pone.0199687>
- Maroof, M., Pamei, G., Bhatt, M., Awasthi, S., Bahuguna, S. C., & Singh, P. (2022). Drug adherence to anti-tubercular treatment during COVID-19 lockdown in Haldwani block of Nainital district. *Indian Journal of Community Health*, 34(4 SE-Original Article), 535–541. <https://doi.org/10.47203/IJCH.2022.v34i04.016>
- Medicaid.gov. (2020). *Telemedicine: centers for Medicare and Medicaid services*. Telemedicine. <https://www.medicaid.gov/medicaid/benefits/telemedicine/index.html>
- Mbuh, T.P. *et al.* (2019) “Bacteriologically confirmed extra pulmonary tuberculosis and treatment outcome of patients consulted and treated under program conditions in the littoral region of Cameroon 11 Medical and Health Sciences 1103 Clinical Sciences,” *BMC Pulmonary Medicine*, 19(1). Available at: <https://doi.org/10.1186/s12890-018-0770-x>.

- Milkias, H., Yewhalaw, D., & Abebe, G. (2023). High non-compliance rate among presumptive tuberculosis cases referred from peripheral health facilities in silti district of Southern Ethiopia: a mixed methods study. *Archives of Public Health*, 81(1), 50. <https://doi.org/10.1186/s13690-023-01071-w>
- Moynihan, R. *et al.* (2021) “Impact of COVID-19 pandemic on utilisation of healthcare services: a systematic review,” *BMJ Open*, 11(3), p. e045343. Available at: <https://doi.org/10.1136/bmjopen-2020-045343>.
- Mwansa-Kambafwile, J. R. M., Chasela, C., Levin, J., Ismail, N., & Menezes, C. (2022). Treatment initiation among tuberculosis patients: the role of short message service (SMS) technology and Ward-based outreach teams (WBOTs). *BMC Public Health*, 22(1), 318. <https://doi.org/10.1186/s12889-022-12736-6>
- Nezenega, Z. S., Perimal-Lewis, L., & Maeder, A. J. (2020). Factors Influencing Patient Adherence to Tuberculosis Treatment in Ethiopia: A Literature Review. *International Journal of Environmental Research and Public Health*, 17(15). <https://doi.org/10.3390/ijerph17155626>
- Nunes-Alves, C. *et al.* (2014) “In search of a new paradigm for protective immunity to TB,” *Nature Reviews Microbiology*. Nature Publishing Group, pp. 289–299. Available at: <https://doi.org/10.1038/nrmicro3230>.
- Orooj, M., Sharma, B., Rabra, S., & Awasth, S. (2021). Impact of COVID-19 pandemic on quality of life and medication adherence among pulmonary Tb patients. *International Journal of Current Research and Review*, 13(6), 119–124.
- Ouzzani, M, *et al.* (2016) Rayyan a web and mobile app for systematic reviews, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5139140/>
- Pan, Z. *et al.* (2020) “The gap between global tuberculosis incidence and the first milestone of the who end tuberculosis strategy: An analysis based on the global burden of disease 2017 database,” *Infection and Drug Resistance*, 13, pp. 1281–1286. Available at: <https://doi.org/10.2147/IDR.S248875>.
- Pandey, A.K. and Sassetti, C.M. (2008) “Mycobacterial persistence requires the utilization of host cholesterol,” *Proc Natl Acad Sci USA*, 105(11), pp. 4376–4380. Available at: <https://doi.org/10.1073/pnas.0711159105>.



Pengurus Besar Ikatan Dokter Indonesia (2017) *Panduan Praktik Klinis Bagi Dokter di Fasilitas Pelayanan Kesehatan Primer*. Jakarta.

Philips, J.A. and Ernst, J.D. (2012) “Tuberculosis pathogenesis and immunity,” *Annual Review of Pathology: Mechanisms of Disease*, pp. 353–384. Available at: <https://doi.org/10.1146/annurev-pathol-011811-132458>.

Pradipta, I.S. *et al.* (2018) “Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis,” *Journal of Infection*. W.B. Saunders Ltd, pp. 469–478. Available at: <https://doi.org/10.1016/j.jinf.2018.10.004>.

Pratama, R. A., Diniarti, F., & Tita Septi Handayani. (2023). Faktor-Faktor Yang Mempengaruhi Kepatuhan Minum Obat Pada Pasien TB Paru Kasus Baru Di RSUD Curup Tahun 2022. *Jurnal Sains Dan Kesehatan*, 12(1 SE-Articles), 25–36. <https://journal.bengkuluinstitute.com/index.php/sainskesehatan/article/view/376>

Ravimohan, S. *et al.* (no date) “Tuberculosis and lung damage: from epidemiology to pathophysiology.” Available at: <https://doi.org/10.1183/16000617.0077>.

Restrepo, R. *et al.* (2010) “Imaging of round pneumonia and mimics in children,” *Pediatric Radiology*, 40(12), pp. 1931–1940. Available at: <https://doi.org/10.1007/s00247-010-1767-7>.

Rhatomy, S. and Prasetyo, T.E. (2020) “Impact of COVID-19 on primary care visits: lesson learnt from the early pandemic period,” *Journal of Community Empowerment for Health*, 3(2), p. 102. Available at: <https://doi.org/10.22146/jcoemph.57918>.

Roy, A. *et al.* (2021) “Mental health implications of COVID-19 pandemic and its response in India,” *International Journal of Social Psychiatry*, 67(5), pp. 587–600. Available at: <https://doi.org/10.1177/0020764020950769>.

RS Paru dr. Ario Wirawan (2019) *RENCANA STRATEGIS BISNIS RS Paru dr. Ario Wirawan Salatiga periode 2020-2024*. Salatiga. Available at: www.rspaw.or.id.

Rumende, C.M. (no date) *Diagnosis dan Tatalaksana Tuberkulosis Resistan Obat*.

Russell, D.G. *et al.* (2009) “Foamy macrophages and the progression of the human tuberculosis granuloma,” *Nature Immunology*, pp. 943–948. Available at: <https://doi.org/10.1038/ni.1781>.

- Sahile, Z., Maeder, A. J., Perimal-Lewis, L., & Arbon, P. (2023). Mobile-assisted medication adherence support intervention among tuberculosis patients: a parallel group randomized control trial. *Population Medicine*, 5(Supplement). <https://doi.org/10.18332/popmed/163638>
- Schwartz, N., Price, S., & Pratt, R. (2020). Tuberculosis - United States. *Morb Mortal Wkly Rep*, 69(11), 286–289.
- Seifert, M. *et al.* (2015) “Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: A systematic review,” *PLoS ONE*, 10(3). Available at: <https://doi.org/10.1371/journal.pone.0119628>.
- Shuka, Z., Mebratie, A., Alemu, G., Rieger, M., & Bedi, A. S. (2022). Use of healthcare services during the COVID-19 pandemic in urban Ethiopia: evidence from retrospective health facility survey data. *BMJ Open*, 12(2), e056745. <https://doi.org/10.1136/bmjopen-2021-056745>
- Sipahutar, T. and Eryando, T. (2020) “COVID-19 Case Fatality Rate and Detection Ability in Indonesia,” *Kesmas: National Public Health Journal*, 15(2). Available at: <https://doi.org/10.21109/kesmas.v15i2.3936>.
- Soeroto, A.Y. *et al.* (2021) “Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study,” *PLOS ONE*, 16(2), p. e0246284. Available at: <https://doi.org/10.1371/journal.pone.0246284>.
- Spruijt, I., Alam, Y., Nguyen, H., Myrzaliev, B., Ahmatov, M., Odume, B., Mtei, L., Gebhard, A., Gidado, M., & Jerene, D. (2023). Digital health solutions and integrated COVID-19 and TB services to help recover TB care and prevention services in the COVID-19 pandemic: A descriptive study in four high TB burden countries. *PLOS ONE*, 18(11), e0293964. <https://doi.org/10.1371/journal.pone.0293964>
- Susilawati, T. N., & Larasati, R. (2019). A recent update of the diagnostic methods for tuberculosis and their applicability in indonesia: A narrative review. *Medical Journal of Indonesia*, 28(3), 284–291.
- Surendra, H. *et al.* (2021) “Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study,” *The Lancet Regional Health - Western Pacific*, 9, p. 100108. Available at: <https://doi.org/10.1016/j.lanwpc.2021.100108>.



- Terracciano, E. *et al.* (2020) “Tuberculosis: an ever present disease but difficult to prevent,” *Ig Sanita Pubbl*, 76(1), pp. 59–66.
- Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., ... & Straus, S. E. (2018). PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Annals of internal medicine*, 169(7), 467-473.
- Wagstaff, A., van Doorslaer, E., & Burger, R. (2019). SMS nudges as a tool to reduce tuberculosis treatment delay and pretreatment loss to follow-up. A randomized controlled trial. *PloS One*, 14(6), e0218527. <https://doi.org/10.1371/journal.pone.0218527>
- Wang, W., Tang, J. and Wei, F. (2020) “Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China,” *Journal of Medical Virology*, 92(4), pp. 441–447. Available at: <https://doi.org/10.1002/jmv.25689>.
- Warner, D.F. (2015) “Mycobacterium tuberculosis metabolism,” *Cold Spring Harbor Perspectives in Medicine*, 5(4). Available at: <https://doi.org/10.1101/cshperspect.a021121>.
- World Health Organization (2021) *GLOBAL TUBERCULOSIS REPORT 2021*. Available at: <http://apps.who.int/bookorders>.
- World Health Organization (no date) *Global tuberculosis report 2019*.
- Wu, Y.-C., Chen, C.-S. and Chan, Y.-J. (2020a) “The outbreak of COVID-19: An overview,” *Journal of the Chinese Medical Association*, 83(3), pp. 217–220. Available at: <https://doi.org/10.1097/JCMA.0000000000000270>.
- Wu, Y.-C., Chen, C.-S. and Chan, Y.-J. (2020b) “The outbreak of COVID-19: An overview,” *Journal of the Chinese Medical Association*, 83(3), pp. 217–220. Available at: <https://doi.org/10.1097/JCMA.0000000000000270>.
- Wulandari, D.H., Administrasi, D. and Kesehatan, K. (no date) *Analisis Faktor-Faktor yang Berhubungan dengan Kepatuhan Pasien Tuberkulosis Paru Tahap Lanjutan Untuk Minum Obat di RS Rumah Sehat Terpadu Tahun 2015*.
- Xing, W. *et al.* (2021) “Adherence to multidrug resistant tuberculosis treatment and case management in chongqing, china – a mixed method research study,” *Infection and Drug Resistance*, 14, pp. 999–1012. Available at: <https://doi.org/10.2147/IDR.S293583>.
- Yin, X. *et al.* (2012) “Development and Validation of a Tuberculosis Medication Adherence Scale,” *PLoS ONE*. Available at: <https://doi.org/10.1371/journal.pone.0050328>.